RxDoctor Payments DataLook up a doctor →

Aron Adkins, MD

Endocrinology, Diabetes & Metabolism · Eau Claire, WINPI 1336246529

Payments from drug & device makers

$349,259in general payments, 2019–2025

Across 808 payments — averaging $432.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$170K
  • Dexcom, Inc.$58K
  • AstraZeneca$41K
  • Bayer$26K
  • Medtronic$19K
  • Abbott$16K
  • plus $19K from 12 others

What the payments were for

  • Consulting fees$5,2502%
  • Speaking & faculty fees$310,30089%
  • Travel & lodging$21,9176%
  • Food & beverage$11,6953%
  • Education$960%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$349,259 in reported general payments places this provider in the 95th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.

See all endocrinology, diabetes & metabolism providers in Wisconsin

Medicare billing

Part B allowed, 2024
$406,174
Medicare patients
1,606
Services billed
11,688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide251$365,954
MounjaroTirzepatide206$240,222
FarxigaDapagliflozin Propanediol166$166,483
TrulicityDulaglutide106$131,489
Tresiba Flextouch U-200Insulin Degludec89$88,189
JardianceEmpagliflozin82$82,875
KerendiaFinerenone65$66,301
InvokanaCanagliflozin67$58,111
Tresiba Flextouch U-100Insulin Degludec104$55,939
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog75$55,824
RybelsusSemaglutide17$48,095
ForteoTeriparatide12$45,528
Novolog FlexpenInsulin Aspart143$43,630
Semglee (Yfgn) PenInsulin Glargine-Yfgn55$43,067
TymlosAbaloparatide15$37,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Forteo$28$417,239324 claims
Novo NordiskOzempic, Rybelsus$169,752$414,049268 claims
AstraZenecaFarxiga$40,727$166,483166 claims
Boehringer IngelheimJardiance$11$82,87582 claims
BayerKerendia$25,994$66,30165 claims
Johnson & JohnsonInvokana$13,839$58,11167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.

Other endocrinology, diabetes & metabolism in Eau Claire

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →